KCT0007003招募中未知
azertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer which is not amenable to treatment with a curative aim (e.g. surgery or radiation).
- •2.Confirmed uncommon EGFR mutations (e.g. G719X, S768I, L861Q, G719X + S768I, G719X + L861Q, L861Q + S768I, L747S, S720A, E709A, exon 18 deletion) without common EGFR mutations including exon 19 deletion, L858R, exon 20 insertion, or T790M. (The result from both cell-free DNA or tissue-based DNA is allowed.)
- •3.Age of 20 or more.
- •4.Performance status of Eastern Cooperative Oncology Group 0 to 2.
- •5.At least one measurable lesion by RECIST 1.1(The part of radiation treatment in the palliative setting is excluded.)
- •6.Untreated asymptomatic brain metastasis or symptomatic brain metastasis treated with local treatment such as operation, whole brain radiotherapy, or gamma-knife surgery, and stable and not requiring steroids for at least 2 weeks prior to start of study treatment.
- •7.At least 2 weeks later after whole brain radiotherapy or palliative thoracic radiotherapy
- •8.Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5 x 109/L; hemoglobin > 9.0g/dL; platelets > 100 x 109/L; total bilirubin =1.5 UNL; AST and/or ALT < 2.5 ULN if no demonstrable liver metastases or < 5 UNL in the presence of liver metastases; CCr = 50mL/min
- •9.Written informed consent form
排除标准
- •1.Previously treatment with any kind of EGFR TKI
- •2.Uncontrolled central nervous system metastases
- •3.Leptomeningeal carcinomatosis
- •4.Uncontrolled systemic illness, including uncontrolled hypertension, active bleeding, or active infection
- •5.Cytotoxic chemotherapy, investigational agents or other anticancer drugs within 14days of first dose of study treatment, or any investigational drugs within 5 x half-lives of the compound
- •6.Major surgery undertaken less than 4 weeks before the study
- •7.Localized palliative radiotherapy unless completed more than 2 weeks before the study
- •8.Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method, contraception until 3 months after discontinuation of drug for female, hormonal methods should be used in combination with barrier methods)
- •9.Prior history of malignancy within 5 years from study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer, early gastric cancer or otherwise confirmed as curative malignancy disease by principal investigator
- •10.Any of the following cardiac criteria:
- •- Prolonged QT interval in ECG (QTc > 450 msec)
- •- Any clinically important abnormalities in rhythm, conduction conduction or morphology of resting ECG eg complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec
- •- Any other factors that increase risk of QT or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 yers og age in first degree relatives or concomitant medications known to prolong QT interval
研究者
相似试验
招募中
不适用
azertinib for NSCLC harboring activating EGFR mutations in TKI naïve patients: A single-arm, phase II single-center trialNeoplasmsKCT0007795Samsung Medical Center150
尚未招募
2 期
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsNSCLCNCT05277701Yonsei University36
尚未招募
Unknown
azertinib and Tepotinib for EGFR mutant NSCLC in MET overexpressed or amplified who progressed after Lazertinib treatmentKCT0009074Samsung Medical Center47
已完成
不适用
A Phase 2 Study of Osimertinib for Advanced NSCLC with Malignant Pleural Effusion Harboring EGFR T790M mutationon-small cell lung cancerJPRN-UMIN000026669The Japan-Multinational Trial Organization25
已完成
2 期
Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutationsadvanced non-small cell lung cancer1003866610029107NL-OMON42560European Thoracic Oncology Platform (ETOP)6